UP!

ACUR $0.49   View long term graphs

Acura Pharmaceuticals Inc.
Type
Public
Traded as NASDAQ:ACUR
Industry Pharmaceutical industry
Founded 1935
Headquarters Palatine, Illinois
Products Pharmaceuticals
Revenue Increase US$ .75 million (2015)
Website acurapharm.com

Acura Pharmaceuticals Inc. is a pharmaceutical company focused on the development and commercialization of deterrents to medication abuse and misuse. As of 2012, the company had several opioid products under development, which would use "Aversion Technology". As of 2014, the company was a publicly traded company, listed on NASDAQ under the symbol "ACUR".

In 2013, the Company settled Oxecta patent litigation with Impax Laboratories (IPXL) and Par Pharmaceutical.

Aversion Technology, provides abuse deterrent benefits to orally administered pharmaceutical drugs. Many of the products approved by the US Food and Drug Administration, such as OXECTA from Pfizer, have incorporated such technology.

Impede Technology is used in easily dissolved tablets and involves the addition of an inactive ingredient polymer matrix, which has been shown to form a thick gel and start a conversion process of crushed pseudoephedrine (PSE). This technology the aims of the Combat Methamphetamine Epidemic Act enacted in the United States in 2006.

The company has an agreement to license, develop and commercialize opioid analgesic products with King Pharmaceuticals.

In 2013, multiple retailers – including Kroger and Fruth Pharmacy – stocked Acura's product Nexafed, which is a drug that attempts to prevent illicit methamphetamine synthesis by incorporating the new pseudoephedrine conversion technology from the company. Nexafed has blocker in it that stops the making of methamphetamine.

News

Acura Pharmaceuticals, Inc. 0.62% (healthcare)

Q reports

Period Date Adjusted Actuals EPS GAAP EPS
Q1 2018 2018-06-29 0.00 -0.07
Q4 2017 2018-06-07 0.00 -0.08
Q3 2017 2017-11-13 0.00 -0.12
Q2 2017 2017-08-14 0.00 -0.18
Q1 2017 2017-05-12 0.00 0.03
Q4 2016 2017-03-31 0.00 0.13
Q3 2016 2016-11-14 0.00 -0.19
Q2 2016 2016-08-08 0.00 -0.28
Q1 2016 2016-05-02 0.00 -0.28
Q4 2015 2016-02-29 0.00 -0.08

Ratings

2016-06-10 Reiterated Rating FBR & Co. Buy
2016-06-10 Reiterated Rating FBR & Co Buy
2016-05-05 Reiterated Rating FBR & Co. Buy $10.00
2016-04-13 Reiterated Rating Roth Capital Buy $6.00
2016-03-11 Initiated Coverage Roth Capital Buy $6.00
2015-10-30 Reiterated Rating FBR & Co. Outperform
2015-07-02 Initiated Coverage MLV & Co. Buy $2.00
2015-06-17 Boost Price Target MLV & Co. Buy $1.00 to $2.00
2015-05-01 Reiterated Rating MLV & Co. Buy $1.00
2015-02-27 Upgrade MLV & Co. Hold to Buy $1.00
2015-01-09 Lower Price Target Roth Capital Buy $1.50 to $1.00
2014-08-15 Reiterated Rating Roth Capital Buy $2.50 to $1.50
2014-05-28 Downgrade MLV & Co Buy to Hold $2 to $1
2014-05-28 Downgrade MLV & Co. Buy to Hold $2.00 to $1.00
2014-05-22 Initiated Coverage Roth Capital Buy $2.50
2014-05-09 Lower Price Target MLV & Co. $2.25 to $2.00
2014-03-05 Boost Price Target MLV & Co. $2.00 to $2.25
2013-08-14 Initiated MLV & Co Buy $4
2016-06-10 Reiterated Rating FBR & Co. Buy
2016-06-10 Reiterated Rating FBR & Co Buy
2016-05-05 Reiterated Rating FBR & Co. Buy $10.00
2016-04-13 Reiterated Rating Roth Capital Buy $6.00
2016-03-11 Initiated Coverage Roth Capital Buy $6.00

There is presents forecasts of rating agencies and recommendations for investors about this ticker

Funds

In ACUR 0 funds of 2183 total. Show all

Fund name Ticker shares

Major Shareholders

Name Relationship Total Shares Holding stocks
CARE CAPITAL II LLC 8.31%  (4058337) ACUR /
WESSON BRUCE F 0.93%  (453927) ACUR / DSCI / MDAS /
EMIGH JAMES F VP Corporate Development 0.90%  (439660) ACUR /
Jones Robert B President and CEO 0.84%  (412555) ACUR /
CLEMENS PETER A Senior VP and CFO 0.73%  (355182) ACUR /
Seiser Robert A VP, Controller & Treasurer 0.66%  (322490) ACUR /
Brzeczko Albert W VP Technical Affairs - APT 0.65%  (316000) ACUR /
SKELLY WILLIAM G 0.38%  (187868) ACUR /
ROSS GEORGE K 0.30%  (144339) ACUR /
THANGARAJ IMMANUEL 0.12%  (59526) ACUR /

Comments